[go: up one dir, main page]

AU2001270204A1 - Modulation of beta-amyloid levels by beta-secretase bace2 - Google Patents

Modulation of beta-amyloid levels by beta-secretase bace2

Info

Publication number
AU2001270204A1
AU2001270204A1 AU2001270204A AU7020401A AU2001270204A1 AU 2001270204 A1 AU2001270204 A1 AU 2001270204A1 AU 2001270204 A AU2001270204 A AU 2001270204A AU 7020401 A AU7020401 A AU 7020401A AU 2001270204 A1 AU2001270204 A1 AU 2001270204A1
Authority
AU
Australia
Prior art keywords
beta
bace2
secretase
modulation
amyloid levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270204A
Inventor
Barbara Cordell
Yu-Wang Liu
Diana Hom Quon
Frauke Schimmoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU2001270204A1 publication Critical patent/AU2001270204A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001270204A 2000-06-28 2001-06-27 Modulation of beta-amyloid levels by beta-secretase bace2 Abandoned AU2001270204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21572900P 2000-06-28 2000-06-28
US60/215,729 2000-06-28
PCT/US2001/020465 WO2002000913A2 (en) 2000-06-28 2001-06-27 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2

Publications (1)

Publication Number Publication Date
AU2001270204A1 true AU2001270204A1 (en) 2002-01-08

Family

ID=22804142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270204A Abandoned AU2001270204A1 (en) 2000-06-28 2001-06-27 Modulation of beta-amyloid levels by beta-secretase bace2

Country Status (6)

Country Link
US (3) US6713276B2 (en)
EP (2) EP1315516A2 (en)
JP (1) JP2004501652A (en)
AU (1) AU2001270204A1 (en)
CA (1) CA2413209A1 (en)
WO (1) WO2002000913A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
JP5138851B2 (en) * 1999-06-28 2013-02-06 オクラホマ メディカル リサーチ ファウンデーション Catalytically active recombinant memapsin and methods of use thereof
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7341991B2 (en) * 2003-12-31 2008-03-11 Posco Inhibitors of amyloid precursor protein processing
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
AU2006307314C1 (en) 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP2061771A1 (en) * 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
CN101668751A (en) 2006-12-12 2010-03-10 先灵公司 aspartyl protease inhibitors
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2147914B1 (en) * 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (en) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
CA2707309A1 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US20090176711A1 (en) * 2008-01-08 2009-07-09 Chi-Bom Chae Inhibitors of amyloid precursor protein processing
EA020740B1 (en) 2008-06-13 2015-01-30 Шионоги & Ко., Лтд. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
CN102186841A (en) * 2008-10-22 2011-09-14 盐野义制药株式会社 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity
SG171932A1 (en) * 2008-12-02 2011-07-28 Hoffmann La Roche Screening assays for the identification of bace2 inhibitors
EP2370579B1 (en) 2008-12-04 2017-03-29 CuRNA, Inc. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
TWI488852B (en) 2009-12-11 2015-06-21 Shionogi & Co Purine derivative
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co Fused aminodihydropyrimidine derivative
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
CN103608345A (en) 2011-04-26 2014-02-26 盐野义制药株式会社 Oxazine derivative and BACE 1 inhibitor containing same
JP2013158281A (en) * 2012-02-03 2013-08-19 Shionogi & Co Ltd Novel method for measuring bace1 activity
JP2015511494A (en) 2012-03-15 2015-04-20 キュアナ,インク. Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF)
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507782A (en) 1990-06-15 1994-09-08 サイオス ノバ インコーポレイテッド Non-human recombinant mammals exhibiting amyloid formation symptoms of Alzheimer's disease
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
EP0848062A3 (en) 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartic protease ASP1
AU1726199A (en) 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
US20030224517A1 (en) * 2002-06-04 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme 2 expression
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20060101532A1 (en) * 1999-04-30 2006-05-11 Nixon Ralph A Methods for the identification of compounds for the treatment of Alzheimer's disease
US7087399B1 (en) * 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
PE20010693A1 (en) 1999-09-23 2001-06-24 Upjohn Co METHOD FOR THE DETERMINATION OF ALFA-SECRETASE ACTIVITY ON THE APP
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
CA2313828A1 (en) * 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
AU2002243391A1 (en) * 2000-10-27 2002-06-24 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
US20040203042A1 (en) * 2003-03-04 2004-10-14 Johnson Jason M Alternatively spliced isoforms of aspartyl protease 1 (BACE2)

Also Published As

Publication number Publication date
US7183070B2 (en) 2007-02-27
EP2359847A1 (en) 2011-08-24
JP2004501652A (en) 2004-01-22
US20070224656A1 (en) 2007-09-27
US20040248231A1 (en) 2004-12-09
CA2413209A1 (en) 2002-01-03
US6713276B2 (en) 2004-03-30
WO2002000913A9 (en) 2002-10-24
WO2002000913A3 (en) 2003-03-13
US20020159991A1 (en) 2002-10-31
WO2002000913A2 (en) 2002-01-03
EP1315516A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2001270204A1 (en) Modulation of beta-amyloid levels by beta-secretase bace2
AU2001294926A1 (en) Antisense modulation of smad6 expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2002213467A1 (en) Modulation of ccr4 function
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2001278077A1 (en) Antisense modulation of ptp1b expression
AU2001276934A1 (en) Methods of modulating fibrosis
AU2001294196A1 (en) Nitrogenous five-membered ring compounds
AU5009200A (en) Novel beta-secretase and modulation of beta-secretase activity
AU2001261808A1 (en) Antisense modulation of pten expression
AU2324100A (en) Positive resist composition of chemical amplification type
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU6109200A (en) Antisense modulation of shp-2 expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2001288968A1 (en) Antisense modulation of btak expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU6114100A (en) Antisense modulation of mekk1 expression
AU2001267091A1 (en) Transdifferentiation of glial cells
AU5874800A (en) Antisense modulation of ets-2 expression
AU2001293545A1 (en) Modulation of meiotic recombination
AU2002362800A1 (en) Modulation of the expression of genes dependent on stat-1